中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

152 records (took 0.021 seconds)

    MODIFIED CELL LINE AND METHOD OF DETERMINING TAUOPATHIES
    65.
    发明申请
    MODIFIED CELL LINE AND METHOD OF DETERMINING TAUOPATHIES 审中-公开
    修饰的细胞系和确定TAUOPATHIES的方法

    公开(公告)号：WO2017172764A1

    公开(公告)日：2017-10-05

    申请号：PCT/US2017/024536

    申请日：2017-03-28

    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA ,  DAIICHI SANKYO COMPANY, LIMITED

    Inventor： WOERMAN, Amanda L. ,  OLSON, Steven ,  AOYAGI, Atsushi ,  PRUSINER, Stanley B. ,  PATEL, Smita ,  KAZMI, Sabeen

    IPC: C07K14/47 ,  G01N33/68

    Abstract: A cell line comprised of cells stably transfected with (a) a nucleotide sequence encoding repeat domains of a 4R tau isoform; and (b) a nucleotide sequence encoding repeat domains of a 3R tau isoform. The cell line is used in a variety of methods which make it possible to identify and quantify a range of tauopathies including Alzheimer's disease, chronic traumatic encephalopathy, and progressive super nuclear palsy.

    Abstract translation: （a）编码4R tau同种型的重复结构域的核苷酸序列稳定转染的细胞组成的细胞系; 和（b）编码3R tau同种型的重复结构域的核苷酸序列。 该细胞系用于各种方法中，这些方法可以鉴定和定量一系列tau蛋白病，包括阿尔茨海默氏病，慢性创伤性脑病和进行性超级核麻痹。

    NANOCRYSTALS FORMED IN A MICROENVIRONMENT
    66.
    发明申请
    NANOCRYSTALS FORMED IN A MICROENVIRONMENT 审中-公开
    微环境中形成的纳米晶

    公开(公告)号：WO2017123315A2

    公开(公告)日：2017-07-20

    申请号：PCT/US2016/060824

    申请日：2016-11-07

    Applicant: ARADIGM CORPORATION

    Inventor： CIPOLLA, David C. ,  GONDA, Igor

    IPC: A61K9/127 ,  A61K31/496

    CPC classification number: A61K9/127 ,  A61K9/0078 ,  A61K9/1277 ,  A61K31/496 ,  A61K47/26

    Abstract: A formulation is disclosed which is comprised of a first solvent having a first active ingredient dissolved therein a plurality of microenvironments dispersed in the first solvent, the microenvironment being comprised of a spherical shell having a diameter in a range of 0.5 micron to 100 microns, the shell comprising an internal volume comprising a second solvent having a second active ingredient dissolved therein and nanocrystals of the second active ingredient.

    Abstract translation: 公开了一种配制剂，其由第一溶剂和第二溶剂组成，所述第一溶剂具有溶解于其中的多个微环境的第一活性成分，所述微环境分散在第一溶剂中，所述微环境由直径范围 为0.5微米至100微米，所述壳包含内部体积，所述内部体积包含溶解有第二活性成分的第二溶剂和所述第二活性成分的纳米晶体。

    PROGRAMMABLE MONITORING SYSTEM
    67.
    发明申请
    PROGRAMMABLE MONITORING SYSTEM 审中-公开
    可编程监控系统

    公开(公告)号：WO2014152799A2

    公开(公告)日：2014-09-25

    申请号：PCT/US2014/027779

    申请日：2014-03-14

    Applicant: ALCHERA INCORPORATED D/B/A SERVANDUS

    Inventor： LLOYD, Lester John ,  LLOYD, Timothy Patrick ,  YAZOLINO, Lauren Felix

    IPC: G08C19/00

    CPC classification number: H04Q9/00 ,  G08B21/02 ,  G08B21/04 ,  G08B21/0407 ,  G08B21/0423 ,  H04Q2209/40 ,  H04Q2209/50 ,  H04Q2209/823

    Abstract: The programmable monitoring system comprises one or more motion sensors, one or more temperature sensors, one or more door sensors and one or more pill box sensors. Each sensor is tagged with a unique code readable by a smart phone camera and software program which allows alarms on the smart phone to be set. The alarms are individually set for any or all of the sensors based on habits of the person being monitored.

    Abstract translation: 可编程监控系统包括一个或多个运动传感器，一个或多个温度传感器，一个或多个门传感器以及一个或多个药盒传感器。 每个传感器都标有一个智能手机摄像头可读的唯一代码，以及允许设置智能手机上的闹钟的软件程序。 这些警报是根据被监测人员的习惯为任何或所有传感器单独设置的。

    VACCINE FORMULATION OF MANNOSE COATED PEPTIDE PARTICLES
    68.
    发明申请
    VACCINE FORMULATION OF MANNOSE COATED PEPTIDE PARTICLES 审中-公开
    疫苗制剂的MANNOSE涂层肽颗粒

    公开(公告)号：WO2012125567A2

    公开(公告)日：2012-09-20

    申请号：PCT/US2012/028779

    申请日：2012-03-12

    Applicant: FLOW PHARMA INC. ,  HERST, Charles Vincent Taylor ,  RUBSAMEN, Reid M.

    Inventor： HERST, Charles Vincent Taylor ,  RUBSAMEN, Reid M.

    IPC: A61K31/765 ,  A61K9/14 ,  A61P37/04

    CPC classification number: A61K9/167 ,  A61K9/145 ,  A61K9/146 ,  A61K9/1623 ,  A61K9/1647 ,  A61K9/5015 ,  A61K39/00 ,  A61K39/39 ,  A61K2039/55555 ,  A61K2039/575 ,  A61K2039/64

    Abstract: A vaccine formulation as disclosed which is comprised of a pharmaceutically acceptable carrier in a plurality of particles with mannose on their surface. The particles are comprised of a biocompatible polymer which maybe a co-polymer such as PLGA combined with a peptide of a sequence which corresponds to a sequence on a surface of a pathogen. A plurality of different groups of particles are provided in the formulation wherein the particles within any single group include peptides of identical amino acid sequence. The particles are sized such that they are sufficiently large so as to prevent more than a single particle from being presented to a single immune system cell.

    Abstract translation: 所公开的疫苗制剂，其由在其表面上具有甘露糖的多个颗粒中的药学上可接受的载体组成。 颗粒由生物相容性聚合物组成，其可以是共聚物如PLGA与对应于病原体表面上的序列的序列的肽结合。 在制剂中提供多个不同组的颗粒，其中任何单一组中的颗粒包括相同氨基酸序列的肽。 这些颗粒的尺寸使得它们足够大，以便防止多于单个颗粒被提供给单个免疫系统细胞。

    NEEDLE-FREE INJECTORS AND DESIGN PARAMETERS THEREOF THAT OPTIMIZE INJECTION PERFORMANCE
    70.
    发明申请
    NEEDLE-FREE INJECTORS AND DESIGN PARAMETERS THEREOF THAT OPTIMIZE INJECTION PERFORMANCE 审中-公开

    公开(公告)号：WO2012037268A3

    公开(公告)日：2012-03-22

    申请号：PCT/US2011/051617

    申请日：2011-09-14

    Applicant: ZOGENIX, INC. ,  BOYD, Brooks ,  SCHUSTER, Jeffrey A.

    Inventor： BOYD, Brooks ,  SCHUSTER, Jeffrey A.

    IPC: A61M5/30

    Abstract: A needle free injector system and a method for delivering a formulation using this system are disclosed. The method comprises actuating a needle free injector to pressurize a liquid formulation and force the formulation through an orifice in a skin puncture phase followed by injection of the formulation during a delivery phase. The skin puncture phase is defined by a pressure profile vs. time curve after actuation which has a main pressure peak with a maximum pressure. The delivery phase occurs at a lower pressure than the maximum pressure of the main peak pressure. The device may have one or more orifices and pressurizing the formulation during the puncture phase and delivery phase to extrude the formulation through each orifice is structured so as to improve characteristics of needle free delivery.

Patent Agency Ranking